Stock Price & Analysis

Based on the analysis of Elevance Health (ELV) stock, it is recommended to buy as the stock has a strong buy rating from analysts with a mean price target of $485.13, indicating a potential upside of 13.1% from the current price of $428.67. However, investors should be cautious due to mixed Q4 results and Medicaid attrition concerns.

Elevance Health (ELV) stock is predicted to reach $440-$460 in 2025. This forecast is based on strong analyst upgrades, with Barclays raising its target to $512 and Truist Securities adjusting to $480, alongside ELV's 16% year-to-date stock price increase. The stock's current price of $428.67, combined with a mean analyst target of $485.13, supports this bullish outlook.

The S1 support level for ELV Stock is $422.25 ,The R1 resistant level for ELV Stock is $436.8.

As of the end of day on 2025-04-01, the price of ELV Stock was $432.68.

The target price for ELV Stock according to analyst rating is 470.79, with the highest price target at 512.00 and the lowest at 405.00. Analysts have a Strong Buy rating on ELV Stock overall.

The market cap of ELV is $98.0B.

ELV may be moderately overvalued based on its PE ratio and PB ratio compared to industry averages, but other metrics like EV/EBITDA and PS ratio suggest reasonable valuation. Analysts maintain a Buy rating with a price target above current levels.

Elevance Health, Inc. is a health company. It operates as a health insurer in the United States. The Company operates through four segments: Health Benefit, CarelonRx, Carelon Services, and Corporate & Other. The Health Benefits segment offers a comprehensive suite of health plans and services to Individual, employer group risk-based, employer group fee-based, BlueCard, Medicare, Medicaid and federal employees health benefits (FEHB) program members. The CarelonRx segment includes its pharmacy business. CarelonRx markets and offers pharmacy services to affiliated health plan customers, as well as to external customers outside of the health plans. It also offers infusible and injectable therapies. Carelon Services offers healthcare-related services and capabilities to internal and external customers including integrated care delivery, behavioral health, palliative care, utilization management, payment integrity services and subrogation services, as well as health and wellness programs.

Elevance Health (ELV) stock is predicted to reach $650 by 2030, driven by strong financials, a "Strong Buy" analyst consensus, and sector growth. The stock's current price of $428.67, combined with a mean target of $485.13 and a high target of $625, supports this bullish outlook.

ELV has a total of 104900 employees.